Halozyme Therapeutics (HALO) – PRNewswire
-
Halozyme to Report First Quarter 2024 Financial and Operating Results
-
Halozyme to Participate in Upcoming Investor Conferences
-
HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL AND OPERATING RESULTS
-
Halozyme To Report Fourth Quarter and Full Year 2023 Financial and Operating Results
-
Halozyme Announces Takeda Received European Commission Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
-
Halozyme Announces argenx Received Approval in Japan for VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Co-Formulated with ENHANZE® for Generalized Myasthenia Gravis
-
Halozyme Announces Takeda Receives FDA Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
-
Halozyme Announces Roche Receives European Commission Approval of Tecentriq® SC with ENHANZE® Representing the EU's First Subcutaneous PD-(L)1 Cancer Immunotherapy for Multiple Cancer Types
-
Halozyme to Host Investor Business Forum and Long-Term Outlook Call
-
Halozyme to Present at Upcoming Investor Conferences
-
Halozyme Announces argenx Receives European Commission Approval of VYVGART® SC with ENHANZE® for Generalized Myasthenia Gravis
-
HALOZYME REPORTS THIRD QUARTER 2023 FINANCIAL AND OPERATING RESULTS
-
Halozyme and Acumen Pharmaceuticals Enter Global Collaboration and Non-Exclusive License Agreement for the ENHANZE® Technology in Alzheimer's Disease
-
Halozyme To Report Third Quarter 2023 Financial and Operating Results
-
Positive Topline Results Reported from Bristol Myers Squibb's Phase 3 CheckMate-67T Trial of Subcutaneous Nivolumab with Halozyme's ENHANZE® Drug Delivery Technology for Advanced or Metastatic Clear
-
Update: Halozyme Announces Presentation of Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery at 13th Annual PODD: Partnership Opportunit
-
Halozyme Announces Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery
-
Halozyme to Present at Upcoming Investor Conferences
-
Halozyme Announces Approval of Roche's Tecentriq® Subcutaneous (SC) with ENHANZE® in Great Britain
-
HALOZYME REPORTS SECOND QUARTER 2023 FINANCIAL AND OPERATING RESULTS
-
Halozyme To Report Second Quarter 2023 Financial and Operating Results
-
Positive Topline Data Reported from argenx's ADHERE Study of VYVGART® Hytrulo with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Chronic Inflammatory Demyelinating Polyneuropathy
-
Positive Results Announced from Phase 3 OCARINA II Trial Evaluating Roche's OCREVUS® (ocrelizumab) with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Multiple Sclerosis
-
Halozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo With ENHANZE® for Subcutaneous Use in Generalized Myasthenia Gravis
-
Halozyme to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
-
HALOZYME REPORTS FIRST QUARTER 2023 FINANCIAL AND OPERATING RESULTS
-
Halozyme To Report First Quarter 2023 Financial and Operating Results
-
HALOZYME PROVIDES UPDATE ON LICENSEE CO-FORMULATION PATENT HEARING IN EUROPE
-
HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL AND OPERATING RESULTS
-
Halozyme to Report Fourth Quarter and Full Year 2022 Financial and Operating Results
-
Halozyme Appoints Barbara Duncan to its Board of Directors
-
HALOZYME THERAPEUTICS, INC. ANNOUNCES REDEMPTION OF 1.25% CONVERTIBLE SENIOR NOTES DUE 2024
-
Halozyme Provides 2023 Financial Guidance and Outlook
-
Halozyme to Present at the 41st Annual J.P. Morgan Healthcare Conference
-
Halo Collective Reports Highest Selling Quarter for Budega Retail Locations and Plans to Continue Expansion
-
Halozyme to Participate in Upcoming Investor Conferences
-
HALOZYME REPORTS THIRD QUARTER 2022 FINANCIAL AND OPERATING RESULTS
-
Halozyme to Report Third Quarter 2022 Financial and Operating Results
-
Halo Collective Completes Acquisition of Premium Indoor Grow and Distribution Hub in Portland, Oregon
-
Halozyme to Participate in the 2022 Wells Fargo Healthcare Conference
-
/R E P E A T -- Halo Collective Reports Second Quarter 2022 Financial Results/
-
Halo Collective Reports Second Quarter 2022 Financial Results
-
Halozyme Therapeutics, Inc. Announces Upsize and Pricing of Private Offering of $625 Million of Convertible Senior Notes due 2028
-
Halozyme Therapeutics, Inc. Announces Proposed Offering of $500 Million of Convertible Senior Notes due 2028
-
/R E P E A T -- Halo Collective Appoints Katie Field as Chairman of the Board/
-
Halo Collective Appoints Katie Field as Chairman of the Board
-
Halo Collective Receives All Regulatory Approvals for its Third Budega™ Dispensary in Hollywood, Halo's first Superstore
-
HALOZYME REPORTS SECOND QUARTER 2022 FINANCIAL AND OPERATING RESULTS
-
Halo Collective Announces Initiatives to Enhance Shareholder Value
-
Positive Results Announced from Phase III IMscin001 Study Evaluating Subcutaneous Formulation of Tecentriq® with ENHANZE® in Advanced Non-Small Cell Lung Cancer
Back to HALO Stock Lookup
